Teclistamab (JNJ-64007957), a fully humanized IgG4 anti-BCMA/CD3 bispecific MoAb, has shown activity in pre-clinical and phase I-II studies (NCT03145181 and NCT04557098) in R/R MM, with an ORR of 63%, an MRD negativity rate of 26.7%, and a median PFS of 11.3 months [96,97]. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.